Dr. Vatakis, appointed as Medical Director, brings decades of clinical trial leadership, advancing Synbio's credibility and the integrity of its upcoming feasibility trial New York City, October 22, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Synbio International Inc.
New York, NY, October 08, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Synbio International Inc. (OTC: SYIN) (“Synbio” or the “Company”) is pleased to announce the execution of a Share Purchase Agreement and Warrant Agreement (SPA) with FacialDx, Inc.
| Software Industry | Information Technology Sector | Giacinto Claudio Solitario CEO | OTC PINK Exchange | 63888X102 CUSIP |
| US Country | 1 Employees | - Last Dividend | - Last Split | - IPO Date |